The Economic impact of ME/CFS: Individual and societal costs

Description:

This article discusses the economic impact of Myalgic Encephalopathy and Chronic Fatigue Syndrome by examining the direct and indirect costs to the individual and to society.

Creator(s):
Creation Date: April 8, 2008
Partner(s):
UNT College of Arts and Sciences
Collection(s):
UNT Scholarly Works
Usage:
Total Uses: 42
Past 30 days: 5
Yesterday: 0
Creator (Author):
Jason, Leonard A.

Depaul University

Creator (Author):
Benton, Mary C.

Wichita State University

Creator (Author):
Valentine, Lisa M.

University of North Texas

Creator (Author):
Johnson, Abra

Depaul University

Creator (Author):
Torres-Harding, Susan

Roosevelt University

Publisher Info:
Publisher Name: BioMed Central
Place of Publication: [London, United Kingdom]
Date(s):
  • Creation: April 8, 2008
Description:

This article discusses the economic impact of Myalgic Encephalopathy and Chronic Fatigue Syndrome by examining the direct and indirect costs to the individual and to society.

Degree:
Department: Psychology
Note:

Background: ME/CFS is characterized by debilitating fatigue in addition to other physical and cognitive symptoms. It is estimated to affect over 800,000 adults in the U.S. ME/CFS often results in diminished functionality and increased economic impact. The economic impact of an illness is generally divided into two categories: direct and indirect costs. Despite high prevalence rates and the disabling nature of the illness, few studies have examined the costs of ME/CFS at the individual and societal level. In fact, of the four studies examining the economic impact of ME/ME/CFS only two used a U.S. sample. The current study used community and tertiary samples to examine the direct costs of ME/CFS. Methods: Using archival data, Study 1 examined the direct cost of ME/CFS in a community-based sample in Chicago. Study 2 estimated the direct cost of ME/CFS in a tertiary sample in Chicago. Both Study 1 and Study 2 assessed direct costs using office visit costs, medical test costs, and medication costs. Results: For Study 1, the annual direct total cost per ME/CFS patient was estimated to be $2,342, with the total annual direct cost of ME/CFS to society being approximately $2 billion. In Study 2, the annual direct was estimated to be $8,675 per ME/CFS patient, with the total annual direct cost of ME/CFS to society being approximately $7 billion. Conclusion: Using ME/CFS prevalence data of 0.42 and indirect costs estimates from Reynolds et al. (2004), the direct and indirect cost of ME/CFS to society was estimated to be $18,677,912,000 for the community sample and $23,972,300,000 for the tertiary sample. These findings indicate that whether or not individuals are recruited from a community or tertiary sample, ME/CFS imposes substantial economic costs.

Physical Description:

8 p.

Language(s):
Subject(s):
Keyword(s): ME/CFS | economic impacts | societal costs
Source: Dynamic Medicine, 2008, London: BioMed Central
Partner:
UNT College of Arts and Sciences
Collection:
UNT Scholarly Works
Identifier:
  • DOI: 10.1186/1476-5918-7-6
  • ARK: ark:/67531/metadc122163
Resource Type: Article
Format: Text
Rights:
Access: Public
Citation:
Publication Title: Dynamic Medicine
Volume: 7
Issue: 6
Peer Reviewed: Yes